Multiple sclerosis treatment 2001.
Trials of new MS drugs now require MR imaging and clinical data and entail enormous expense. Therefore, science can ask and answer only a limited number of questions, so physicians must use their clinical acumen to judge (or conjecture) the best treatments for their patients. The drugs discussed earlier will dominate MS therapy in the next few years, but further advances may come from one of the more than forty new agents now under investigation for alleviating MS. It is an exciting time for patients and their doctors.
Rolak
L A
LA
Marshfield Clinic, WI 54449, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009462:Neurology / Q000639:trends*; D010455:Peptides / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone; D000068556:Interferon beta-1a